1. Abraham RT, Wiederrecht GJ (1996) Immunopharmacology of rapamycin. Annu Rev Immunol 14: 483–510
2. Alexandre J, Raymond E, Depenbrock H (1999) CCI-779, a new rapamycin analog, has antitumour activity at doses inducing only mild cutaneous effects and mucositis: early results of an ongoing phase 1 study. Proceedings of the AACR/NCI/EORTC International Conference on Molecular Targets and Cancer Therapeutics. Washington, DC, November 16–19
3. Aronica SM, Katzellenbogen B (1991) Progestrogene receptor regulation in uterine cells: stimulation by oestrogen, cyclic adenosine 3,5-monophosphate, and insulin like growth factor I and suppression by antioestrogens and protein kinase inhibitors. Endocrinology 128: 2045–2052
4. Atkin MB, Hidalgo M, Stadler W, Logan T, Dutcher JP, Hudes G, Park Y, Marshall B, Boni J, Dukart G (2002) A randomises phase 2 study of intravenous CCI-779 administered weekly to patients with advanced renal cell carcinoma. Meeting Proceedings American Society of Clinical Oncology: vol 21: Poster Presentation Abst 36
5. Barbet NC, Schneider U, Helliwell SB, Stansfield I, Tuite MF, Hall MN (1996) TOR controls translation initiation and early G1 progression in yeast. Mol Biol Cell 7: 25–42